BACKGROUND AND AIMS: Integrins such as alpha(2)beta(1), alpha(IIb)beta(3), and alpha(v)beta(3) have been suggested as key players for cancer development and progression. Several polymorphisms affecting these molecules, two in integrin alpha(2) (ITGA2 807C>T and 1648G>A) and one in beta(3) (ITGB3 176T>C), influence their levels, structure, and possibly their function. To analyze the role of ITGA2 and ITGB3 polymorphisms for colorectal cancer risk and clinical presentation, we performed a case-control study. MATERIALS AND METHODS: Four hundred thirty-three colorectal cancer patients and 433 healthy sex- and age-matched control subjects were investigated. ITGA2 and ITGB3 polymorphisms were determined by 5'-nuclease assays. RESULTS/ FINDINGS: The ITGA2 807C>T polymorphism was associated with reduced colorectal cancer risk. In a codominant model, the odds ratio for each additional 807-T allele for colorectal cancer was 0.77 (95% confidence interval 0.64-0.94; p = 0.011). The ITGA2 1648G> and the ITGB3 176T>C polymorphism were not associated with colorectal cancer. None of the three polymorphisms investigated was associated with tumor size, histological grade, presence of primary lymph node metastases, tumor stage, or age at diagnosis. INTERPRETATION/ CONCLUSION: We conclude that the ITGA2 807C>T polymorphism may be associated with reduced colorectal cancer risk.
BACKGROUND AND AIMS: Integrins such as alpha(2)beta(1), alpha(IIb)beta(3), and alpha(v)beta(3) have been suggested as key players for cancer development and progression. Several polymorphisms affecting these molecules, two in integrin alpha(2) (ITGA2 807C>T and 1648G>A) and one in beta(3) (ITGB3 176T>C), influence their levels, structure, and possibly their function. To analyze the role of ITGA2 and ITGB3 polymorphisms for colorectal cancer risk and clinical presentation, we performed a case-control study. MATERIALS AND METHODS: Four hundred thirty-three colorectal cancerpatients and 433 healthy sex- and age-matched control subjects were investigated. ITGA2 and ITGB3 polymorphisms were determined by 5'-nuclease assays. RESULTS/ FINDINGS: The ITGA2 807C>T polymorphism was associated with reduced colorectal cancer risk. In a codominant model, the odds ratio for each additional 807-T allele for colorectal cancer was 0.77 (95% confidence interval 0.64-0.94; p = 0.011). The ITGA2 1648G> and the ITGB3 176T>C polymorphism were not associated with colorectal cancer. None of the three polymorphisms investigated was associated with tumor size, histological grade, presence of primary lymph node metastases, tumor stage, or age at diagnosis. INTERPRETATION/ CONCLUSION: We conclude that the ITGA2 807C>T polymorphism may be associated with reduced colorectal cancer risk.
Authors: B Felding-Habermann; T E O'Toole; J W Smith; E Fransvea; Z M Ruggeri; M H Ginsberg; P E Hughes; N Pampori; S J Shattil; A Saven; B M Mueller Journal: Proc Natl Acad Sci U S A Date: 2001-02-13 Impact factor: 11.205
Authors: Jie Chen; Nan-Nan Liu; Jia-Qi Li; Li Yang; Ying Zeng; Xiao-Mei Zhao; Lin-Lin Xu; Xuan Luo; Bin Wang; Xue-Rong Wang Journal: World J Gastroenterol Date: 2011-06-21 Impact factor: 5.742
Authors: Ana Cecilia Cepeda-Nieto; María Teresa Esquivel-Contreras; Francisco Duran-Iñiguez; Mauricio Andrés Salinas-Santander; Hugo Leonid Gallardo-Blanco; Sandra Cecilia Esparza-González; Alejandro Zugasti-Cruz; Jesús Antonio Morlett-Chávez; Luis Tlaloc Córdova-Alvelais Journal: Exp Ther Med Date: 2015-05-26 Impact factor: 2.447
Authors: Marion Lavergne; Emily Janus-Bell; Mathieu Schaff; Christian Gachet; Pierre H Mangin Journal: Cancers (Basel) Date: 2017-09-28 Impact factor: 6.639